Background. Human brucellosis is usually treated with a combination of tetracyclines and aminoglycosides. However, the optimal duration of therapy has not been clearly determined.
The optimal duration of antibiotic treatment in patients with brucellosis is unclear, even for the most common clinical presentation of acute, uncomplicated brucellosis without focal disease [1] . Traditionally, treatment with a tetracycline for 30-45 days combined with a 7-21-day course of aminoglycoside therapy (streptomycin or gentamicin) is recommended for symptomatic brucellosis without focal disease, and longer courses weeks) are recommended if endocarditis, spondylitis, or neurobrucellosis is present [2] .
Although data are limited, studies of classic treatment combinations of tetracycline and streptomycin show that longer treatment durations result in lower relapse rates among adult patients with brucellosis [3] [4] [5] . Furthermore, longer durations of treatment with the less classic drug combination of doxycycline plus gentamicin also appears to reduce relapse rates. A preliminary study by our group [6] demonstrated that the relapse rate among patients receiving 30-day treatment with oral doxycycline combined with 7-day treatment with gentamicin (im once daily) was 22.9%, compared with 5.9% among patients receiving doxycycline for 45 days and the same 7-day dose of gentamicin. Nevertheless, the optimal duration of treatment for acute brucellosis must reflect a balance between the risk of relapse when treatment is prematurely discontinued and the risk of toxic effects and other inconveniences of prolonged antimicrobial therapy. If a shorter course of antibiotic treatment was as efficacious as a longer course of therapy without increasing relapse rates, this could result in decreased treatment costs, improved patient adherence, and decreased adverse effects. Because the optimal duration of doxycycline administration within the doxycycline-gentamicin regimen has not been studied through a comparative trial, we undertook a randomized, double-blind, controlled trial comparing 30-day and 45-day courses of doxycycline combined with a 7-day course of intramuscular gentamicin.
PATIENTS AND METHODS

Study Design and Enrollment Criteria
The study was a randomized, double-blind, controlled trial comparing 30-day and 45-day courses of doxycycline therapy combined with a 7-day course of gentamicin, for the treatment for acute brucellosis. Patients were recruited from 5 general hospitals in central Spain between July 1995 and January 1999. The study was approved by the institutional review boards of each participating center, and written, informed consent was obtained from all participating patients.
Eligible patients were у18 years of age with brucellosis diagnosed on the basis of at least 1 of the following criteria: isolation of Brucella species from samples of blood or other fluids or tissues; detection of antibodies to Brucella species at a titer of у1:160 by use of a standard tube agglutination method; or a у4-fold increase in the Brucella antibody titer to 11:80, revealed by standard tube agglutination, between serum specimens obtained у2 weeks apart and studied in the same laboratory. Additionally, at least 2 of the following compatible clinical findings must have been present: fever, arthralgias, weight loss, hepatosplenomegaly, or signs of focal disease. Patient exclusion criteria included known or suspected hypersensitivity (or another contraindication) to tetracyclines or aminoglycosides, severe concomitant disease, body weight of !50 kg, or receipt of effective antimicrobial therapy for brucellosis р30 days before entering the study. We also excluded patients with endocarditis, spondylitis, or neurobrucellosis, because these conditions necessarily involve longer-term antibiotic therapy than that provided in this study.
Randomization and Treatment
At the start of the trial, a master list of computer-generated random treatment assignments was stored at the Pharmacy Department at the General Hospital in Albacete, Spain. Subjects were assigned to receive either doxycycline (100 mg po b.i.d.) for 30 days plus placebo for an additional 15 days (30-day group) or the same dosage of doxycycline for 45 days (45-day group). Randomization was stratified according to the clinical center and was done to equalize treatment assignments in blocks of 4 subjects, maintaining a 1:1 ratio between subjects in the 45-day group and those in the 30-day group. Neither patients nor investigators were aware of the treatment assignment. In addition, all subjects received gentamicin (240 mg im once daily) during the first 7 days of treatment. Capsules of doxycycline and placebo were prepared by Laboratorios Wasserman.
Outcome and Follow-Up Measurements
Therapeutic efficacy and drug toxicity. At baseline and on days 7, 30, and 46 (end of therapy) of the trial, clinical data were recorded; complete blood cell counts and erythrocyte sedimentation rates were measured; urinalysis was performed; creatinine, aspartate aminotransferase, alkaline phosphatase, albumin, total protein, bilirubin, and electrolyte levels were determined; Brucella serological analysis was performed; and blood samples were cultured. Patients in either therapy group who did not experience a complete clinical response (i.e., signs and symptoms of disease were still manifest at day 30 of the trial) were withdrawn from the study. Subjects who did have a complete response by day 30 continued the study (receiving doxycycline or placebo) for the remaining 15 days. Drug safety was assessed on the basis of all reported adverse events and the results of laboratory tests and other investigations.
Compliance. During the treatment phase of the study, compliance was checked at each visit (days 7, 30, and 46) by counting the pills remaining in drug containers and analyzing blood samples to determine levels of doxycycline and gentamicin. Patients were judged to be compliant if they had taken 190% of the required dose since the last visit.
Relapse. Patients were reassessed for relapse of brucellosis at months 1, 2, 3, 6, 9, and 12 after the end of therapy, as well as whenever clinical symptoms reappeared. Relapse was defined as reappearance of symptoms or signs of the disease (as assessed by the patient's physician) or a new positive result of blood culture within the 12-month period after the end therapy. Data were collected until relapse or conclusion of the trial (12 months after the end of therapy), whichever came first.
Special Laboratory Studies
The standard tube agglutination test, the rose bengal test, and the anti-Brucella Coombs test were done with commercial reagents, according to standard methods [7] . Blood samples were cultured as reported elsewhere [8] , and cultures were incubated for 30 days by use of the Bactec system (Becton Dickinson Diagnostic Instrument Systems). Doxycycline concentrations were measured in serum from whole blood samples that were collected just before administration of a new dose of doxycycline. Doxycycline was extracted at a central reference laboratory by methods described elsewhere [9] . 
Statistical Analysis
Before undertaking the study, we calculated that a sample size of 194 patients would be needed to achieve 80% power at a 2-tailed a level of .05, on the basis of an assumption that overall relapse rates would be reduced from 20% in the 30-day group to 5% in the 45-day group, with a dropout rate of 10% [10] . However, decreased incidence of brucellosis in Castilla-La Mancha resulted in a patient recruitment rate that was slower than predicted. The study was therefore discontinued after 4 years, and statistical analyses were done for the 167 patients recruited up to January 1999.
Analyses were done according to the intention-to-treat rule. The x 2 test or Fisher's exact test were used to compare categorical variables between the 2 groups, and Student's t test or the Wilcoxon rank sum test were used to compare continuous variables. The primary aim of analysis was to compare rates of relapse in the 2 groups. Because the duration of follow-up was !1 year for many patients, the probabilities of relapse and their SEs were estimated by survival analysis techniques, and the treatment groups were compared by means of a log rank test [11] . Cox proportional hazards regression analysis [12] was used to estimate the difference between the 2 treatment groups after adjustment for the following baseline covariates: study center, age, sex, duration of symptoms before therapy, focal disease, and isolation of Brucella species in blood cultures.
was considered to be statistically significant. All P values P ! .05 are 2-tailed.
RESULTS
Patient characteristics.
A flow chart summarizing the process by which patients were selected for analysis is shown in figure 1. Between September 1995 and January 1999, a total of 198 patients were screened for entry into the study. Of these, 167 underwent randomization; 84 were assigned to receive doxycycline for 30 days (30-day group), and 83 were assigned to receive doxycycline for 45 days (45-day group). Of these patients, 11 in the 30-day group and 10 in the 45-day group did not complete the treatment phase of the study and were excluded from all analyses because spondylitis was detected after randomization (3 patients in each group), brucellosis was mistakenly diagnosed (4 in the 30-day group and 2 in the 45-day group), the patient did not attend follow-up examinations (2 in the 30-day group and 3 in the 45-day group), the patient requested that treatment be stopped (2 in the 45-day group), or the treating physician requested that treatment be stopped Forty-five days posttherapy, the percentage of patients with relapse was significantly higher in the 30-day group than in the 45-day group (12.33% vs. 1.37%; relative risk, 9.00; 95% CI, 1.17-69.2;
). From day 45 after the start of therapy P p .017 through the end of the 12-month follow-up period, an additional 6 patients (9.38%) of the 64 remaining nonrelapsed patients at 30 days after the end of treatment and 8 patients (11.11%) of the 72 remaining nonrelapsed patients at 45 days after the end of treatment (risk ratio, 0.84; 95% CI, 0.31-2.30;
). During the course of study period, relapses occurred P p .78 in 15 (20.55%) of 73 patients in the 30-day group and in 9 (12.33%) of 73 patients in the 45-day group (relative risk, 1.67; 95% CI, 0.78-3.56;
). P p .264 The cumulative probability of nonrelapse is summarized in figure 2 . In the 30-day group, there was a sharp increase in the ). Vertical dashes, patient withdrawals. P p .130 rate of relapse immediately after cessation of antibiotic therapy, whereas in the 45-day group, there was no exponential increase in relapse rates at any point posttherapy. From ∼1 month after initiation of therapy through the end of the study, similar patterns of essentially linear increases in relapse rates, which gradually tapered off during the 12-month follow-up period, were observed for both groups. ). However, the P p .046 results of multivariate analyses encompassing all of the baseline variables listed in table 2 indicate that treatment with doxycycline for 30 days was the only factor significantly associated with relapse (hazard ratio, 2.51; 95% CI, 1.04-6.05;
). P p .04 Adverse effects. The frequency of adverse effects was similar in both groups (table 3) , occurring in 29 (40%) of 73 patients in the 30-day group and 28 (38%) of 73 patients in the 45-day group. The most frequently observed adverse effects were phototoxicity (18 patients in the 30-day group and 13 patients in the 45-day group) and gastrointestinal complaints (17 patients [8 and 9, respectively] experienced epigastric discomfort, and 4 patients [1 and 3, respectively] experienced nausea or vomiting), both of which were considered to be related to doxycycline. Most of these reactions were classified as mild; that is, toxic effects were not severe enough to result in discontinuation of therapy. The intramuscular administration of gentamicin was well tolerated. Mild pain at the site of injection occurred only rarely, and no change in therapy was required. Laboratory studies did not reveal any drug-related hematopoietic or renal abnormalities.
DISCUSSION
The primary objective of our double-blind study was to assess which of 2 treatment regimens for acute brucellosis-doxycycline for 45 days plus gentamicin for 7 days or doxycycline for 30 days plus gentamicin for 7 days-was more effective in reducing relapse rates while minimizing adverse effects. We found that the 45-day regimen significantly reduced relapses during the first 45 days after the start of therapy, but differences in rates of relapse between the 2 groups were no longer significant 145 days after therapy initiation. Treatment with doxycycline for 45 days did not increase the incidence of adverse effects.
On the basis of results of this study, it appears that shorter, 30-day courses of doxycycline increase vulnerability to breakthrough cases of brucellosis р6 weeks after the start of treatment. The longer, 45-day treatment seems to delay the occurrence of relapse until at least 1 month after therapy is started. Although the difference in overall rates of relapse throughout the follow-up period was not statistically significant between groups (20.55% in the 30-day group and 12.33% in the 45-day group), doxycycline treatment for 45 days resulted in fewer relapses (9 patients), compared with the 30-day group (15 patients). Treatment with courses of doxycycline and/or gentamicin than are longer than those administered in the current study may be necessary to achieve even lower relapse rates. Additional studies comparing efficacy and safety of long-course therapy (e.g., doxycycline for 145 days and/or gentamicin for 17 days) with short-course doxycycline plus gentamicin for patients with Brucella infection should clarify this issue. Also, a larger sample size may have been needed to reveal significant differences in relapse rates between the 2 treatments used in the current study.
Baseline blood cultures positive for Brucella species are known risk factors for relapse of the disease [13, 14] . Therefore, it is noteworthy that, in both treatment groups in this study, the relapse rate for the subgroup of patients with positive blood culture results at baseline was very high. However, multivariate analyses still revealed the 30-day treatment regimen to be the most significant factor in predicting relapse.
To our knowledge, the present trial of treatment for acute brucellosis resulted in higher numbers of patients with relapse than were found in several other controlled studies to date [2, 3] . One reason for the higher relapse rates observed in our study may be associated with the methods used to detect relapse. We used not only exhaustive clinical surveillance of patients but also microbiological analysis to detect relapse. In fact, 6 patients in our study were defined as having relapse on the basis of microbiological analysis only, without presentation of overt clinical signs and symptoms. The study by Lubani et al. [15] , in which no relapses were observed among children receiving combinations of doxycycline for 3, 5, or 8 weeks and gentamicin for 5 days, did not include follow-up microbiological analysis. However, in a study that used blood culture methods and also evaluated doxycycline plus gentamicin regimens for the treatment of brucellosis in children, Abramson et al. [16] observed relapse rates of 20% among patients who received short-course therapy, which are similar to rates observed in our present study. Therefore, the sensitivity of methods used to detect relapse should be taken into account when evaluating the efficacy of drug combinations in published studies; a successfully cured patient in 1 study may be classified as having bacteriological relapse in another.
Nevertheless, the current trial of doxycycline plus gentamicin resulted in higher relapse rates than those in other studies involving 45-and 30-day regimens of doxycycline and 2-3-week courses of streptomycin and microbiologic controls [5, 8, [17] [18] [19] [20] . Streptomycin may be a more effective treatment than gentamicin for treatment of brucellosis, or a longer duration of gentamicin treatment may be required to achieve the same therapeutic outcome as streptomycin. Because no published studies compare doxycycline plus streptomycin with doxycycline plus gentamicin, we recommend, until further notice, the use of classic regimens of doxycycline for 45 days with streptomycin for 14-21 days if relapse is to be avoided. However, in countries in which it is difficult to obtain streptomycin, gentamicin can be substituted, but we suggest a 2-week treatment time rather than the 7-day course used in the present study.
This study has several practical implications. Although the optimal duration and combination of drug therapy for the treatment of acute brucellosis remains unresolved, physicians can consider that longer durations of doxycycline treatment reduce the incidence of relapse (even if only during the first 1 or 2 months after the end of therapy) and do not appear to increase adverse effects. Because overall relapse rates were not markedly different between the short-and medium-course therapy tested in our study, patients can potentially opt for the treatment regimen that best suits their circumstances. It follows that blood cultures should be done for all patients with acute brucellosis, both to confirm the diagnosis and to better predict the clinical and bacteriologic outcome. Furthermore, exhaustive clinical and microbiological follow-ups detect more relapses. Therefore, patients should not be pronounced as cured unless microbiological testing confirms the absence of bacteremia. Finally, even if relapse of brucellosis does occur, it is reassuring that, whatever the drug regimen used, nearly all patients are cured with a second course of the same antibiotic therapy [2] .
In treating acute human brucellosis, we have demonstrated that there are no significant differences between the efficacies of 30-and 45-day courses of doxycycline treatment. Nevertheless, the 45-day regimen can be considered superior, because relapse rates during the 45-day period after initiation of therapy were significantly reduced without an increase in adverse effects. This advantage assumes special importance in areas where access to medical care is limited, making early relapses potentially more difficult and/or costly to treat.
